Exclusive: Beat-Down, Tariff-Proof Auto Parts Stock Ready to Rebound
A precision medicine biotech debuts its IPO, an oversold salvage auction giant signals a buying opportunity, a circuit board maker eyes a strong earnings beat, and a floral retailer’s high short interest hints at a squeeze. Here’s what to watch this week.

One Asset Thrives in Chaos (Sponsored)
Markets are on edge as tensions rise between two of America’s most powerful figures—Trump and Musk.
With inflation rising, banks pulling back, and stocks swinging wildly, retirement accounts are more exposed than ever.
But one asset class has quietly gained value during every major crisis: physical gold.
Discover how to protect wealth and roll over eligible accounts into gold—without paying taxes or penalties.
CLAIM YOUR FREE GOLD IRA GUIDE NOW
The window to protect your wealth is closing fast. Act now before the next headline sends markets into freefall.


Jabil
Ticker: JBL | Market Cap: $18.9B | Catalyst: Earnings on Tuesday
Jabil’s Q3 FY’25 earnings, due Tuesday, should showcase strength, with consensus expecting $2.30 EPS (up 20% year-over-year) and $7B in revenue (up 4%). Recent growth in capital equipment, cloud, and digital commerce, plus a 40% surge in AI-related revenue to $7.5B, fuels optimism.
Historically, Jabil’s posted positive one-day post-earnings returns 70% of the time over five years (14 of 20 quarters), with a median gain of 5.7%. Even with per-share pricing climbing nearly 50% over the past year, the trend leans bullish.
At just under $20B market cap and $1.3B operating profit, Jabil’s poised for a potential pop, however brief, barring unexpected headwinds.

Crisis-Ready Strategy (Sponsored)
A little-known financial change goes live this July—one that major institutions are quietly preparing for now.
Big Banks have found a new asset class they trust more than stocks, bonds, or even cash.
As Peter Schiff put it: “It’s now the only form of money trusted by the banking system.”
This isn’t a theory—it’s already happening and everyday investors still relying on traditional assets may be exposed.
A free, IRS-approved strategy shows how to move retirement funds into this secure, physical asset—tax-free.


Accenture
Ticker: ACN | Market Cap: $195B | Catalyst: Earnings on Friday
Accenture’s Q3 2025 earnings, due June 20th, project $3.29 EPS on $17.27B revenue, up 5% year-over-year. Management’s $16.9B - $17.5B guidance and 5% - 7% full-year outlook align, with margins up slightly to 15.6%.
A beat’s likely but won’t spark a surge (last quarter’s beat saw shares dip). I’m eyeing GenAI bookings ($1.4B last quarter, up 16.6%) and M&A plans. Client spending, U.S. Federal contract risks, and CEO Julie Sweet’s tone on margins and growth will be important levers for post-earnings action.
Without bolder growth past 5% or margin fixes, Accenture’s overvalued, with downside risk. I’m staying cautious, expecting no major upside.


1-800-FLOWERS.COM
Ticker: FLWS | Market Cap: $315.9M | Catalyst: High Short Interest
1-800-FLOWERS.COM carries a hefty 75% short interest, signaling bearish bets on its floral and gift delivery business. Priced at multi-year lows, it’s not a standout stock, but the setup implies short squeeze potential.
A positive catalyst, like strong seasonal sales or cost-cutting announcements, could force shorts to cover, spiking the price. However, macro headwinds, including tariff uncertainties impacting supply chains, add risk.
FLWS’s fundamentals aren’t stellar, but its beaten-down valuation and high short interest make it a speculative buy for risk-tolerant traders eyeing a quick pop. Monitor for demand surges or tariff clarity.

Next Crypto Boom (Sponsored)
ETFs are flooding crypto markets with institutional capital, and a new wave of opportunity is just beginning.
While most are focused on Bitcoin, 27 of the most trusted crypto insiders are tracking where the smart money is really going.
Their findings will be revealed during the Crypto Community Summit 2025, and access is currently free.
Expect key predictions, altcoin picks, and the next phase of growth few are prepared for.
[Claim Your Free Summit Pass Now]


Copart
Ticker: CPRT | Market Cap: $49.98B | Catalyst: Oversold
Copart, with a sub-$50 share price, is oversold at an RSI of 20, signaling a prime buying opportunity. Despite a recent dip from its $64.38 year-high, its ~$50B market cap reflects a robust online salvage auction empire.
Rising repair costs from complex EVs and tariffs boost salvage demand, while Florida’s storm season and the Hall Ranch acquisition enhance capacity. Solid financials, including $1.3B operating profit, negligible debt, and steady FCF growth, underline its strength.
Though previously overvalued, the current pullback offers long-term investors a compelling entry point, assuming difficult-to-forecast headwinds like uninsured driver rates don’t escalate.


Caris Life Sciences
Ticker: CAI | Catalyst: IPO on Wednesday
Caris Life Sciences’ IPO, set for June 18th, aims to raise $424M, targeting a $5.3B valuation on Nasdaq under ticker CAI. The biotech’s AI-driven oncology platform, leveraging 6.5M tests across 849,000 cases, powers its MI Profile and Caris Assure diagnostics.
Revenue jumped 35% to $412.3M in 2024, though net losses persist at $248.7M. Backed by Sixth Street and Neuberger Berman, Caris rides a hot IPO wave, despite tariff and geopolitical risks.
Strong institutional support and 50% Q1 revenue growth signal upside, but high valuation and losses warrant caution for investors eyeing this precision medicine pioneer.

From a biotech’s high-stakes IPO to an oversold salvage leader’s rebound potential, a circuit board maker’s earnings momentum, and a floral stock’s short squeeze setup, this week’s catalysts could drive sharp market moves. Buckle up and position strategically to seize the volatility.
That’s all for today. Thank you for reading. If you have any feedback, please reply to this email.
Best Regards,
— Jeremy Flint
Elite Trade Club
Click here to get our daily newsletter straight to your cell for free.
P.S. Just like this newsletter, it's 100% free*, and you can stop at any time by replying STOP.
Legal Stuff: Stocks featured in this newsletter are for entertainment purposes only. You should not base any investment decisions on information contained in my newsletter. Stocks featured in this newsletter may be owned by owners/operators of this website, which could impact our ability to remain unbiased. Please consult a financial advisor before making any trading decisions. I may earn a small commission from links placed inside these emails.